Due tothedevelopmentofdrugresistanceandotherlimitationsinthe treat ment of AIDS patients with reverse transcriptase (RT) inhibitors like zidovu dineandothers, itbecamenecessarytoexploreantiviralagentsactingontar getsotherthan RT. Inthepastfewyears, hundredsofHIVproteaseinhibitoLs have been synthesized and tested. Among these protease inhibitors, saquinavir, ritonavir, indinavir and nelfinavir have been marketed during 1995-1997. In this review, emphasis is placed on the development of HIV protease inhibitors as antiviral agents against HIV, structure-activity rela tionship (SAR) analysis ofsaquinavirand relatedcompounds, comparisonof four marketed HIV protease inhibitors, and future prospect in developing new anti-HIV drugs. 2 Introduction HIV protease inhibitors 3 HIV protease as a target for chemotherapy HIV protease was first suggested as a potential target for AIDS therapy by Kramer et a1. in 1986 [5]. HIV protease is a proteolytic enzyme responsible for cleaving large numbers of amino acid sequences. This enzyme regulates conversionoftheselargeaminoacid sequencesintobiologicallyactive struc tural and functional protein products. Specifically, HIV protease is responsi the enzymatic processing of the gagand gag-pol genes of HIV, which ble for encode for functional core proteins and viral enzymes (reverse transcriptase, ribonuclease H, integrase, and HIV protease). The polyproteins encoded by the gagand gag-pol genes undergo post-translational processing by HIV pro tease to form functional protein products as the viral particles budding out from infected cells. Therefore, inhibition of HIV protease by a protease inhibitor results in the release ofimmature, noninfectious viral particles [4].
"synopsis" may belong to another edition of this title.
Seller: Brook Bookstore On Demand, Napoli, NA, Italy
Condition: new. Questo è un articolo print on demand. Seller Inventory # 1BDIXATTLA
Quantity: Over 20 available
Seller: GreatBookPrices, Columbia, MD, U.S.A.
Condition: As New. Unread book in perfect condition. Seller Inventory # 21682640
Seller: Chiron Media, Wallingford, United Kingdom
Paperback. Condition: New. Seller Inventory # 6666-IUK-9783034897983
Quantity: 10 available
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germany
Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Due tothedevelopmentofdrugresistanceandotherlimitationsinthe treat ment of AIDS patients with reverse transcriptase (RT) inhibitors like zidovu dineandothers, itbecamenecessarytoexploreantiviralagentsactingontar getsotherthan RT. Inthepastfewyears, hundredsofHIVproteaseinhibitoLs have been synthesized and tested. Among these protease inhibitors, saquinavir, ritonavir, indinavir and nelfinavir have been marketed during 1995-1997. In this review, emphasis is placed on the development of HIV protease inhibitors as antiviral agents against HIV, structure-activity rela tionship (SAR) analysis ofsaquinavirand relatedcompounds, comparisonof four marketed HIV protease inhibitors, and future prospect in developing new anti-HIV drugs. 2 Introduction HIV protease inhibitors 3 HIV protease as a target for chemotherapy HIV protease was first suggested as a potential target for AIDS therapy by Kramer et a1. in 1986 [5]. HIV protease is a proteolytic enzyme responsible for cleaving large numbers of amino acid sequences. This enzyme regulates conversionoftheselargeaminoacid sequencesintobiologicallyactive struc tural and functional protein products. Specifically, HIV protease is responsi the enzymatic processing of the gagand gag-pol genes of HIV, which ble for encode for functional core proteins and viral enzymes (reverse transcriptase, ribonuclease H, integrase, and HIV protease). The polyproteins encoded by the gagand gag-pol genes undergo post-translational processing by HIV pro tease to form functional protein products as the viral particles budding out from infected cells. Therefore, inhibition of HIV protease by a protease inhibitor results in the release ofimmature, noninfectious viral particles [4]. 340 pp. Englisch. Seller Inventory # 9783034897983
Seller: GreatBookPrices, Columbia, MD, U.S.A.
Condition: New. Seller Inventory # 21682640-n
Seller: Ria Christie Collections, Uxbridge, United Kingdom
Condition: New. In English. Seller Inventory # ria9783034897983_new
Quantity: Over 20 available
Seller: Revaluation Books, Exeter, United Kingdom
Paperback. Condition: Brand New. 326 pages. 9.61x6.69x0.77 inches. In Stock. Seller Inventory # x-3034897987
Quantity: 2 available
Seller: Books Puddle, Woodside, NY, U.S.A.
Condition: New. pp. viii + 326 Index. Seller Inventory # 2698253915
Seller: moluna, Greven, Germany
Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Development of HIV protease inhibitors: A survey.- Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: Current status and therapeutic possibilities.- Peptide drug delivery into the central . Seller Inventory # 4319605
Quantity: Over 20 available
Seller: Majestic Books, Hounslow, United Kingdom
Condition: New. Print on Demand pp. viii + 326. Seller Inventory # 95191940
Quantity: 4 available